Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:03:21 EDT Mon 17 Aug 2026
Enter Symbol
or Name
USA
CA



Z:NNVC - NANOVIRICIDES INC - http://www.nanoviricides.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NNVC - Z0.21.20·1.460.11.38+0.0151.1205.72459641.37  1.40  1.352.2299  0.8519:36:57Aug 1015 min RT 2¢

Recent Trades - Last 10 of 964
Time ETExPriceChangeVolume
19:36:57Z1.3418-0.01821
19:34:11Z1.355-0.0051
19:34:07Z1.355-0.0051
17:08:05Z1.3562-0.0038100
17:07:44Z1.3546-0.0054100
16:21:38Z1.3546-0.0054400
16:13:52Z1.31-0.051,834
16:13:44Z1.31-0.05166
16:13:43Z1.31-0.05500
16:10:05Z1.380.021

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-08-10 08:30U:NNVCNews ReleaseNanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
2026-07-28 08:30U:NNVCNews ReleaseNanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
2026-07-24 08:00U:NNVCNews ReleaseNanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
2026-07-22 08:30U:NNVCNews ReleaseAs Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
2026-07-13 09:27U:NNVCNews ReleaseAs Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
2026-07-08 08:30U:NNVCNews ReleaseResearch Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
2026-07-06 08:30U:NNVCNews ReleaseAs the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
2026-06-29 08:30U:NNVCNews ReleaseUS FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
2026-06-22 09:30U:NNVCNews ReleaseNanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
2026-06-15 08:30U:NNVCNews ReleaseAs the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
2026-06-08 08:30U:NNVCNews ReleaseAs the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies
2026-05-26 08:30U:NNVCNews ReleaseIn the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
2026-05-18 23:55U:NNVCNews ReleaseNanoViricides Announces Closing of ~$2 Million Registered Direct Offering
2026-05-18 08:30U:NNVCNews ReleaseEbola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
2026-05-15 08:35U:NNVCNews ReleaseNanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
2026-05-15 08:00U:NNVCNews ReleaseNanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II
2026-05-11 08:30U:NNVCNews ReleaseRecent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
2026-05-06 15:38U:NNVCNews ReleaseNanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference
2026-05-04 08:30U:NNVCNews ReleaseNV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
2026-04-21 08:30U:NNVCNews ReleaseDeadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides